Inosin, Verbindung mit (2-Hydroxypropyl)dimethylammonium-p-acetamidobenzoat (1:3)
Inosine Pranobex
Grundinformationen
- CAS
36703-88-5- Standard-SMILES
CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O- InChIKey
YLDCUKJMEKGGFI-QCSRICIXSA-N- Summenformel
- C52H78N10O17
- Durchschnittliche Molmasse
- 1.115,2 g/mol
- Monoisotopische Masse
- 1.114,55464106
Überblick
Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Namen und Bezeichner
- Bevorzugter Name
- Inosine Pranobex
- IUPAC
- tris(4-acetamidobenzoic acid);9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;tris(1-(dimethylamino)propan-2-ol)
- Lokaler Name
- Inosin, Verbindung mit (2-Hydroxypropyl)dimethylammonium-p-acetamidobenzoat (1:3)
- Englischer Name
- Isoprinosine
- Summenformel
- C24H34N6O9
- Molmasse
- 550.57
Namen und Synonyme
IsoprinosineINOSINE PRANOBEX36703-88-5InosiplexMethisoprinolImunovirDelimmunIsoviralViruxanIsoprinosinaIsoprinosinAviral
Weitere Namen anzeigen
Metisoprinol25mm13mmnp1130.8um)(1:3)0.22um0.45um
ImunoviralPranosinaModimmunalPranosineNPT-10381W1SO0V223FNP-113Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
Datenbank-Bezeichner
- CAS
36703-88-5- PubChem CID
- 135449284
- DTXSID
DTXSID401021342- ChEMBL
CHEMBL3833327- UNII
- W1SO0V223F
- EC Number
- 253-162-1
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 399 Ų
- H-Brücken-Donoren
- 13
- H-Brücken-Akzeptoren
- 22
- Frei drehbare Bindungen
- 14
- Schwere Atome
- 79
- Formalladung
- 0
- Komplexität
- 658
Physikochemische Eigenschaften
- Schmelzpunkt
- 140 · 140-142°C
- storage temp.
- Inert atmosphere,Room Temperature
- Löslichkeit
- DMSO (Slightly, Heated), Methanol (Slightly, Heated, Sonicated), Water (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Merck
- 14 · 14,4976
- InChIKey
- PBJNZCQJMWVIRT-JHVGCDEENA-N
- SMILES
- O[C@@H]1[C@@H]([C@@H](CO)O[C@H]1N1C=NC2C(N=CNC1=2)=O)O.C(N(C)C)C(O)C.N(C1C=CC(C(=O)O)=CC=1)C(=O)C |&1:1,2,3,7,r|
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 100% (3 of 3) of all reports.
Not Classified
Aggregated GHS information provided per 3 reports by companies from 1 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Other Safety InformationIMAP assessments - Inosine, compound with 1-(dimethylamino)-2-propanol, 4-(acetylamino)benzoate (salt) (1:3): Environment tier I assessment
Hazard Classes and CategoriesNot Classified
Sicherheitsdaten
- hs_code
- 2934.99.9001
- Toxizität
- LD50 in mice and rats (mg/kg): >4000 orally and i.p. (Gordon)
Chemie und Industrie
Pharmakologische Informationen
ATC Code
J - Antiinfectives for systemic use
QJ - Antiinfectives for systemic use
PharmacodynamicsWorks by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.
Mechanism of ActionInosine pranobex stimulates cell-mediated immune processes to viral infections.
Biological Half-Life50 min
MeSH Pharmacological Classification
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Absorption, Distribution and Excretion
Rapidly absorbed from GIT
Via urine
Verwendung und Herstellung
UsesUse (kg; approx.) in Germany (2009): >50
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…